The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines

Anticancer Research

Volumn 31, Issue 3, 2011, Pages 849-854

  Herrera, Vivian Arrias ^a   Zeindl Eberhart, Evelyn ^b   Jung, Andreas ^b   Huber, Rudolf Maria ^a   Bergner, Albrecht ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

BEZ235; EGFR; Lung cancer; P13K mTOR inhibitor

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN S6;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MODELS, BIOLOGICAL; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINOLINES; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 79956078123     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Alberg AJ, Ford JG and Samet JM: Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132: 29S-55S, 2007.
2. Ray M, Salgia R and Vokes EE: The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist 14: 1116-1130, 2009.
3. Hammerman PS, Janne PA and Johnson BE: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 15: 7502-7509, 2009.
4. Yoshida T, Zhang G and Haura EB: Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer. Biochem Pharmacol 80(5): 613-623, 2010.
5. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W and Garcia-Echeverria C: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863, 2008.
6. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garcia-Echeverria C, Weissleder R, Mahmood U, Cantley LC and Wong KK: Effective use of PI3K and MEK inhibitors to treat mutant K-RAS G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356, 2008.
7. Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, Amici A, Boothman DA and Scaglioni PP: Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 69: 7644-7652, 2009.
8. McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC and Mitsiades CS: Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 69: 5835-5842, 2009.
9. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C and Yung WK: NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8: 2204-2210, 2009.
10. Zitzmann K, Ruden JV, Brand S, Goke B, Lichtl J, Spottl G and Auernhammer CJ: Compensatory activation of AKT in response to mTOR and Raf inhibitors - A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 295(1): 100-109, 2010.
11. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C and Maira SM: Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 106: 22299-22304, 2009.
12. Marone R, Erhart D, Mertz AC, Bohnacker T, Schnell C, Cmiljanovic V, Stauffer F, Garcia-Echeverria C, Giese B, Maira SM and Wymann MP: Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res 7: 601-613, 2009.
13. Cao P, Maira SM, Garcia-Echeverria C and Hedley DW: Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 100: 1267-1276, 2009.
14. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, Garcia-Echeverria C, Mercuri M, Picci P and Scotlandi K: NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16: 530-540, 2010.
15. Baumann P, Mandl-Weber S, Oduncu F and Schmidmaier R: The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 315: 485-497, 2009.
16. Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP and Damania B: Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 115: 4455-4463, 2010.
17. Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C and Ghobrial IM: Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 115: 559-569, 2010.
18. de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJ, Planting AS, Nooter K, Stoter G and Sparreboom A: Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19: 3733-3739, 2001. (Pubitemid 32844785)
19. Cadranel J, Zalcman G and Sequist L: Genetic profiling and EGFR-directed therapy in NSCLC: evidence and clinical implications. Eur Respir J 37(1): 183-193, 2011.
20. Pal SK, Figlin RA and Reckamp K: Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther 9: 1931-1944, 2010.